Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
Go back to Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome| (NYSE: UCB) | Delayed: 34.64 -0.2 (0.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.84 | 52 Week High | $ | |||
| Open | $35.14 | 52 Week Low | $ | |||
| Day High | $35.24 | P/E | N/A | |||
| Day Low | $34.62 | EPS | $ | |||
| Volume | 656,766 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 119.74 +1.65 (1.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $118.09 | 52 Week High | $46.25 | |||
| Open | $118.93 | 52 Week Low | $32.74 | |||
| Day High | $120.56 | P/E | N/A | |||
| Day Low | $118.93 | EPS | $0.00 | |||
| Volume | 63,038 | |||||
